Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Recommendation of “Hold” from Brokerages

Posted by Scott Moore on Oct 3rd, 2026

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) have earned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $53.33.

Separately, Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, July 5th.

Read Our Latest Research Report on Reviva Pharmaceuticals

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.50 on Monday. The company has a fifty day moving average of $0.49 and a two-hundred day moving average of $0.64. Reviva Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $17.20. The stock has a market capitalization of $6.55 million, a PE ratio of -0.27 and a beta of 0.50.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19. Research analysts forecast that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors.

Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses.